FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm
Related Articles
FDA grants breakthrough designation for new AI model to detect cardiac amyloidosis in ECG results
Cardiovascular Business: Anumana, a Massachusetts-based healthcare technology company focused on artificial intelligence (AI), has received a breakthrough device designation from the U.S. Food and Drug Administration (FDA) for a new…June 21, 2023
Anumana’s ECG-AI® Algorithms Honored with 2024 MedTech Breakthrough Award for “Best New Technology Solution-Cardiology”
Anumana’s innovative AI algorithms recognized for their transformative potential in cardiology - the first of which is now commercially availableMay 09, 2024
Anumana Collaborates with Novartis Pharmaceuticals Corporation
AI TechPark: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of…July 13, 2022
How a New AI Algorithm Could Help in the Early Detection of Heart Disease
Xtalks: An AI algorithm developed by researchers at the Mayo Clinic through its newly formed health technology company Anumana Inc., can assess for low ejection fraction through routine electrocardiograms (ECG,…May 16, 2021